Supported by

OPTIMISING BREAST CANCER MANAGEMENT DURING COVID-19

CLICK HERE OR SCAN
 TO REGISTER

Sponsored by

00
00
00
00

DAY

HOUR

MINUTE

SECOND

25 MAY 2022
5 - 7 PM Vietnam Time

For healthcare professionals only

SYNOP

The COVID pandemic has changed the way we live. The impact of the pandemic on the management of cancer has been clear - to minimise exposure of cancer patients to coronavirus and adapt alternative treatment delivery options.
Responding to the need for support in the management of Advanced Breast Cancer (ABC) patients during the ongoing pandemic, this webinar will share best practices in the management of ABC patients in Europe and Asia. This webinar also provides the opportunity for real-time interaction between audience and speakers

CHAIRPERSON

SPEAKERS

Prof Marina Cazzaniga

Oncology, School of Medicine and Surgery, University of Milano Bicocca, Italy
Director, Phase 1 Clinical Research Unit, Azienda Socio Sanitaria Territoriale (ASST) di Monza
Founder & President,
International School of Metronomic
Chemotherapy

Consultant, Division of Medical Oncology National Cancer Centre Singapore
President, Singapore Society of Oncology

Dr Elaine Lim

Dr Chun-Yu Liu

Director, Division of Transfusion Medicine, Department of Medicine Taipei Veterans General Hospital, Taiwan

 Welcome Message & Introduction 
 by Chairperson

5.00 pm - Dr Elaine Lim

WEBINAR AGENDA

25 May 2022 from 5 PM tp 7 PM Viet Nam time.

To Refine Treatment Strategies in Advanced Breast Cancer: A Contemporary approach

5.15 pm -  Prof Marina Cazzaniga

Tailored Treatment Strategy with Oral  Chemotherapy during COVID Pandemic, a Taiwan Experience

5.45 pm - Dr Chun-Yu Liu

 Case Study – Singapore Experience 

6.00 pm - Dr Tan Wei Chong

 Panel Discussion

6.15 pm

 Q&A

6.45 pm

 End

7.00 pm

Supported by

Sponsored by

Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise.

The story of
Pierre Fabre

Thanks to our 10,000 employees in 44 subsidiaries and our distribution activities in 130 countries, our group generated €2.3 billion in revenues in 2020, 65% of which is from international business.
Pierre Fabre Group has a unique company structure.
86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan.
This year, the independent organization ECOCERT Environment awarded Pierre Fabre's CSR policy at "excellence" level : - Excellence being the highest maturity level of the ECOCERT 26000 standard. 

2

 largest private French pharmaceutical group

2

largest dermo-cosmetics laboratory in the world

in France for products sold over the counter in pharmacies.

1